ERBB2 and breast carcinoma: The DESTINY-Breast04 study provided strong evidence that trastuzumab delivers significant therapeutic benefit of trastuzumab compared with chemotherapy in advanced breast cancer with low HER2 expression, establishing HER2-low expression as a distinct therapeutic subtype of breast cancer (7, 8).